{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maharaj AR"],"funding":["NICHD NIH HHS","NCATS NIH HHS","NIEHS NIH HHS","FDA HHS","NHLBI NIH HHS","National Institute of Child Health and Human Development","NIH HHS"],"pagination":["499-513"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9706343"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(5)"],"pubmed_abstract":["<h4>Purpose</h4>The aim of this study was to evaluate ceftazidime pharmacokinetics (PK) in a cohort that includes a predominate number of children and adolescents with obesity and assess the efficacy of competing dosing strategies.<h4>Methods</h4>A population PK model was developed using opportunistically collected plasma samples. For each dosing strategy, model-based probability of target attainment (PTA) estimates were computed for study participants using empirical Bayes estimates. In addition, the effects of body size and renal function on PTA were evaluated using stochastic model simulations with virtually generated subjects.<h4>Results</h4>Twenty-nine participants, 24 of whom were obese, contributed data towards the analysis. The median (range) age, body weight, and body mass index o"],"journal":["Paediatric drugs"],"pubmed_title":["Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity."],"pmcid":["PMC9706343"],"funding_grant_id":["R01 FD006099","HHSN267200700051C","UH3 FD006797","UG3 FD006797","R01 HD076676","P30 ES030283","KL2 TR001115","UG1 OD024954","U24 TR001608","HHSN275201000003C","HHSN275201800003I","UG1 HD090904","HHSN275201000003I","R13 HD102136","U18 FD006298","R33 HL147833","K23 HD091398"],"pubmed_authors":["Laughon M","Beci R","Paul IM","Delmore P","Maharaj AR","Hornik CD","Sullivan J","Wade K","Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee","Wu H","Al-Uzri A","Muller WJ","Kennel P","Sherwin CMT","Payne EH","Zimmerman KO","Sullivan JE","Hornik C","Zimmerman K","Benjamin DK","Hornik CP","Autmizguine J","Kearns GL","Rathore MH"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity.","description":"<h4>Purpose</h4>The aim of this study was to evaluate ceftazidime pharmacokinetics (PK) in a cohort that includes a predominate number of children and adolescents with obesity and assess the efficacy of competing dosing strategies.<h4>Methods</h4>A population PK model was developed using opportunistically collected plasma samples. For each dosing strategy, model-based probability of target attainment (PTA) estimates were computed for study participants using empirical Bayes estimates. In addition, the effects of body size and renal function on PTA were evaluated using stochastic model simulations with virtually generated subjects.<h4>Results</h4>Twenty-nine participants, 24 of whom were obese, contributed data towards the analysis. The median (range) age, body weight, and body mass index o","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-05-29T18:52:15.777Z","creation":"2024-11-19T22:29:22.475Z"},"accession":"S-EPMC9706343","cross_references":{"pubmed":["34302290"],"doi":["10.1007/s40272-021-00460-4"]}}